0001679363-24-000012.txt : 20240222 0001679363-24-000012.hdr.sgml : 20240222 20240222070441 ACCESSION NUMBER: 0001679363-24-000012 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240222 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240222 DATE AS OF CHANGE: 20240222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Morphic Holding, Inc. CENTRAL INDEX KEY: 0001679363 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473878772 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38940 FILM NUMBER: 24662255 BUSINESS ADDRESS: STREET 1: 35 GATEHOUSE DRIVE A2 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 996-0955 MAIL ADDRESS: STREET 1: 35 GATEHOUSE DRIVE A2 CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Morphic Holding, LLC DATE OF NAME CHANGE: 20160712 8-K 1 morf-20240222.htm 8-K morf-20240222
0001679363FALSE00016793632024-02-222024-02-22

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________________________________________________________________
FORM 8-K
_______________________________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 22, 2024
_______________________________________________________________________________________
Morphic Holding, Inc.
(Exact Name of Registrant as Specified in its Charter)
______________________________________________________________________________________
Delaware001-3894047-3878772
(State or other jurisdiction of
incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
35 Gatehouse Drive, A2
Waltham,Massachusetts02451
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (781996-0955
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share MORF The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 2.02 Results of Operations and Financial Condition.
On February 22, 2024, Morphic Holding, Inc. issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2023. The Press Release is attached hereto as Exhibit 99.1.

The information in Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.



Item 9.01  Financial Statements and Exhibits
(d) Exhibits
Exhibit
Number
Description
99.1
104The cover page on this Current Report on Form 8-K, formatted in Inline XBRL





SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 MORPHIC HOLDING, INC.
Date: February 22, 2024By:/s/ Marc Schegerin
Marc Schegerin, M.D.
 Chief Financial Officer and Chief Operating Officer


EX-99.1 2 morf-20231231x8kex991.htm EX-99.1 Document
Exhibit 99.1
morphic_brandxrgb-extrasmaa.jpg

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023
-Reported positive results from EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis (UC)-
-Enrollment on target in EMERALD-2 phase 2b global randomized trial of MORF-057 in UC-
-GARNET phase 2 trial of MORF-057 in Crohn’s disease (CD) expected to begin enrolling in the first half of 2024-
-Ended 2023 with $704.3 million in cash and equivalents; cash runway into second half of 2027-
WALTHAM, Mass. – Feb 22, 2024 – Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2023.
“Today, our conviction in MORF-057 as a potential oral, well tolerated, and efficacious treatment for inflammatory bowel disease (IBD) is stronger than ever, based on the clear success of the EMERALD-1 trial in UC. Looking forward in 2024, we will work to translate this momentum into further progress with the GARNET phase 2 study in patients with moderately to severely active Crohn’s disease running in parallel with the EMERALD-2 phase 2b study in UC,” commented Praveen Tipirneni, Chief Executive Officer of Morphic. “Further, we are working to expand the pipeline of candidates generated by Morphic’s MInT Platform, most notably with our α5β1 program for pulmonary hypertensive diseases and additional new projects against both integrin and non-integrin targets
“On a personal note, I am thankful to return to Morphic after an acute medical event and grateful for the immense support from friends and peers within the biotechnology community and especially the Morphic team,” Tipirneni continued. “This experience has crystallized, for me, that Morphic’s opportunity to fundamentally improve patients’ lives is immense and that there is no time to waste.”
2023 and Recent Corporate Highlights
EMERALD-1 Phase 2a trial of MORF-057 in UC:
In the EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis (UC), topline data and additional data presented at UEGW 2023 indicated that in a moderately-to-severely-active UC population with severe disease burden, MORF-057:
Was generally well tolerated with no safety signal observed
Achieved the study’s primary endpoint with statistical significance in reduction of Robarts Histopathology Index (RHI) Score from baseline to week 12 of 6.4 points (p=0.002)
Showed consistent clinical improvement across key measures at week 12, including modified Mayo Clinic Score (mMCS) remission of 25.7% and mMCS response of 45.7%
Demonstrated RHI change ≥7 points in 48.6% of patients and RHI remission in 22.9% of patients
Led to clinical improvement in mMCS within the 12-week induction period for 77% of patients
Pharmacokinetic and pharmacodynamic results confirmed the results seen in healthy volunteer studies
Median α4β7 RO >99% and sustained saturation at week 12
α4β1 inhibition below the limit of quantification, in line with the design of MORF-057
Predicted lymphocyte subset changes observed, consistent with engagement of α4β7
Demonstrated deepening of clinical effect beyond the 12-week induction period, with symptomatic remission rates continuing to increase out to 44 weeks in both advanced treatment-naïve and advanced treatment-experienced patients
Announced completion of enrollment in the exploratory cohort of the EMERALD-1 study comprised of UC patients who have previously failed treatment with vedolizumab
Continued the 40-week maintenance phase of the EMERALD-1 study as planned


EMERALD-2 Phase 2b trial of MORF-057 in UC:
Continued to enroll the EMERALD-2 phase 2b study of MORF-057 in patients with moderately-to-severely active UC
EMERALD-2 is a global phase 2b randomized, double-blind, placebo-controlled trial of MORF-057 in patients with moderate-to-severe UC
The primary endpoint of EMERALD-2 is clinical remission rate as measured by mMCS at 12 weeks and is expected to report in the first half of 2025
GARNET Phase 2 trial of MORF-057 in Crohn’s Disease:
Announced that launch activities are underway for the randomized placebo-controlled GARNET Phase 2 study of MORF-057 in CD and that the study is anticipated to enroll its first patients in the first half of 2024
The GARNET study will evaluate 210 patients across three cohorts, each comprising 70 patients: 70 patients receiving MORF-057 200 mg BID (twice daily), 70 patients receiving MORF-057 100 mg BID and 70 patients receiving placebo
The primary endpoint of the GARNET study is the proportion of participants in endoscopic response (>=50% reduction) at week 14 as determined using Simple Endoscopic Score for Crohn’s Disease (SES-CD)
MORF-057 Preclinical and Phase 1 Studies:
Presented new biomarker data at DDW 2023, demonstrating increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of α4β7 inhibition, supporting MORF-057 program in UC
Presented preclinical data on rational selection of combination therapy for IBD treatment using an established clinical mode at UEGW 2023
This study explored preclinical combination models in UC and preliminarily examined the potential utility and rationale of combining anti-inflammatory mechanisms with α4β7 integrin inhibition in IBD
Pipeline Programs:
Announced α5β1 as the integrin target of Morphic’s small molecule integrin inhibitor program in pulmonary hypertensive diseases
The inhibition of fibronectin integrins, including α5β1, suppresses pulmonary arterial smooth muscle cell proliferation and data to date indicate that inhibition of α5β1 contributes to improved cardiac output and the reversal of vascular remodeling
Initiated discovery efforts that expand the Company’s scope in the immunology space with oral programs targeting the IL-23 and TL1A pathways, among others
Financial Results for the Full Year 2023
Net loss for the year ended December 31, 2023, was $152.1 million or $3.59 per share compared to a net loss of $59.0 million or $1.55 per share for the year ended December 31, 2022
Revenue was $0.5 million for the year ended December 31, 2023, compared to $70.8 million for the year ended December 31, 2022. The change was primarily due to recognition of revenue due to the conclusion of the AbbVie collaboration in 2022 and to the amounts due at the conclusion of the Janssen collaboration in 2023
Research and development expenses were $140.4 million for the year ended December 31, 2023, as compared to $102.1 million for the year ended December 31, 2022. The increase was primarily attributable to higher development costs along with increased clinical trial costs to support phase 2 clinical studies and development activities for MORF-057, as well as other research costs to support early development candidates
General and administrative expenses were $38.8 million for the year ended December 31, 2023, compared to $32.1 million for the year ended December 31, 2022. The increase was due to increased personnel related costs and non-cash equity-based compensation, partially offset by decreases in consulting and insurance expenses

Morphic raised approximately $444 million, net, through equity financings in 2023 comprised of approximately $100 million in proceeds from a PIPE offering, approximately $259 million in a public offering and approximately $85 million though use of the ATM facility
As of December 31, 2023, Morphic had cash, cash equivalents and marketable securities of $704.3 million, compared to $348.2 million as of December 31, 2022. We believe that our cash, cash equivalents and marketable securities of $704.3 million as of December 31, 2023, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2027
About MORF-057
Morphic is developing MORF-057 as a selective, oral small molecule inhibitor of the α4β7 integrin for patients with inflammatory bowel disease (IBD). α4β7 has been clinically validated as a target for the treatment of IBD by the success of the approved injectable antibody therapeutic vedolizumab. MORF-057, like vedolizumab, is designed to block the interactions between α4β7 on the surface of lymphocytes and the mucosal endothelial cell ligand MAdCAM-1, substantially reducing lymphocyte migration from the bloodstream into intestinal mucosal tissues and avoiding inflammation that is associated with IBD.
About the EMERALD-1 Study
EMERALD-1 (MORF-057-201) is an open-label multi-center phase 2a trial designed to evaluate the efficacy, safety, and tolerability of MORF-057 in adults with moderate to severe ulcerative colitis. The primary endpoint of EMERALD-1, change in Robarts Histopathology Index (RHI) from baseline at twelve weeks, was achieved with statistical significance. RHI is a validated instrument that measures histological disease activity in ulcerative colitis. Patients were eligible to continue for an additional 40 weeks of maintenance therapy followed by a 52-week assessment as well as an open-label extension period. Secondary and additional outcome measures in the EMERALD-1 study include change in the modified Mayo clinic score, safety, pharmacokinetic parameters and key pharmacodynamic measures including α4β7 receptor occupancy and lymphocyte subset trafficking.
About the EMERALD-2 Study
EMERALD-2 (MORF-057-202) is a global phase 2b randomized, double-blind, placebo-controlled trial of MORF-057 that is currently enrolling patients with moderate-to-severe ulcerative colitis. The primary endpoint of EMERALD-2 is clinical remission rate as measured by the Modified Mayo Clinic Score (mMCS) at 12 weeks. EMERALD-2 will also measure several secondary and exploratory endpoints based on the mMCS as well as histologic, pharmacokinetic and pharmacodynamic measures, and safety parameters. Patients in the EMERALD-2 study will be randomized to receive either 200 mg BID (twice daily) MORF-057, 100 mg BID MORF-057, a QD (once daily) dose of MORF-057, or a placebo dose. Following the 12-week induction phase, all patients will receive MORF-057 for 40 weeks of maintenance dosing. For more information about the EMERALD clinical trials of MORF-057, please click here.
About the GARNET Study
GARNET (MORF-057-203) is a global Phase 2b randomized, double-blind, placebo-controlled trial of MORF-057 in Crohn’s disease. The primary endpoint of GARNET is the proportion of participants in endoscopic response (>=50% reduction) at week 14 as determined using Simple Endoscopic Score for Crohn’s Disease, or SES-CD. The secondary endpoints will include the change in Crohn’s Disease Activity Index, or CDAI, measures, as well as safety parameters. Patients enrolled in the GARNET study will be randomized to receive one of two active doses or a placebo: 200 mg BID (twice daily), 100 mg BID or a placebo that will cross over to MORF-057 after the 14-week induction phase. Following the 14-week induction phase, patients will move to a 38-week maintenance phase.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the MInT Platform’s ability to discover drug candidates; our plans to develop and commercialize oral small-molecule integrin therapeutics and any proposed timing thereof; the initiation, execution and completion of clinical trials of MORF-057; any expectations about safety, efficacy, timing and ability to commence or complete clinical and pre-clinical studies and/or trials and to obtain regulatory approvals for MORF-057 and other candidates in development; the timing of further data presentation; and the ability of MORF-057 to treat inflammatory bowel disease, including UC, CD, and other indications. Statements including words such as “believe,” “plan,” “continue,” “expect,” “will be,” “develop,” “signal,” “potential,” “anticipate” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause our actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties in this press release and other risks set forth in our filings with the Securities and Exchange Commission, including, among others, our or a partner’s ability to complete a current or future clinical trial of any of our current or future product candidates, our ability to develop or obtain regulatory approval for or commercialize any product candidate, our ability to protect our intellectual property, and the sufficiency of our cash, cash equivalents and investments to fund our operations. These forward-looking statements speak only as of the date hereof and we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.
Financial Tables to Follow



Morphic Holding, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except share and per share data)

Year Ended December 31,
20232022
Collaboration revenue$521 $70,808 
Operating expenses:
Research and development140,384 102,062 
General and administrative38,823 32,142 
Total operating expenses179,207 134,204 
Loss from operations(178,686)(63,396)
Other income:
Interest income, net26,969 4,567 
Other income (expense), net(145)
Total other income, net26,971 4,422 
Loss before provision for income taxes(151,715)(58,974)
Provision for income taxes(380)(67)
Net loss$(152,095)$(59,041)
Net loss per share, basic and diluted$(3.59)$(1.55)
Weighted average common shares outstanding, basic and diluted42,390,554 38,112,498 


Morphic Holding, Inc.
Condensed Consolidated Balance Sheets 
(unaudited)
(in thousands)
December 31, 2023December 31, 2022
Assets
Cash, cash equivalents and marketable securities$704,349 $348,248 
Other current assets12,579 13,934 
Total current assets716,928 362,182 
Other assets5,586 6,407 
Total assets$722,514 $368,589 
Liabilities and Stockholders' Equity
Current liabilities$24,776 $17,126 
Long-term liabilities716 2,344 
Total liabilities25,492 19,470 
Total stockholders' equity697,022 349,119 
Total liabilities and stockholders' equity$722,514 $368,589 

###
Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718
EX-101.SCH 3 morf-20240222.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 morf-20240222_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 morf-20240222_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 morphic_brandxrgb-extrasmaa.jpg begin 644 morphic_brandxrgb-extrasmaa.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
    Cover Page
    Feb. 22, 2024
    Cover [Abstract]  
    Document Type 8-K
    Document Period End Date Feb. 22, 2024
    Entity Registrant Name Morphic Holding, Inc.
    Entity Incorporation, State or Country Code DE
    Entity File Number 001-38940
    Entity Tax Identification Number 47-3878772
    Entity Address, Address Line One 35 Gatehouse Drive, A2
    Entity Address, City or Town Waltham,
    Entity Address, State or Province MA
    Entity Address, Postal Zip Code 02451
    City Area Code 781
    Local Phone Number 996-0955
    Written Communications false
    Soliciting Material false
    Pre-commencement Tender Offer false
    Pre-commencement Issuer Tender Offer false
    Title of 12(b) Security Common Stock, $0.0001 par value per share
    Trading Symbol MORF
    Security Exchange Name NASDAQ
    Entity Emerging Growth Company false
    Entity Central Index Key 0001679363
    Amendment Flag false
    EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://morphictx.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports morf-20240222.htm morf-20240222.xsd morf-20240222_lab.xml morf-20240222_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "morf-20240222.htm": { "nsprefix": "morf", "nsuri": "http://morphictx.com/20240222", "dts": { "inline": { "local": [ "morf-20240222.htm" ] }, "schema": { "local": [ "morf-20240222.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "morf-20240222_lab.xml" ] }, "presentationLink": { "local": [ "morf-20240222_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://morphictx.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "morf-20240222.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "morf-20240222.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://morphictx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001679363-24-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001679363-24-000012-xbrl.zip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͢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morf-20240222_htm.xml IDEA: XBRL DOCUMENT 0001679363 2024-02-22 2024-02-22 0001679363 false 8-K 2024-02-22 Morphic Holding, Inc. DE 001-38940 47-3878772 35 Gatehouse Drive, A2 Waltham, MA 02451 781 996-0955 false false false false Common Stock, $0.0001 par value per share MORF NASDAQ false